Alkem Q4FY26 core profit jumps 41% despite charges

Key takeaway from the March-quarter print

Alkem Laboratories reported a sharp rise in core profitability for Q4FY26, supported by broad-based revenue expansion across India and overseas markets and improving operating leverage. Pre-exceptional profit for the March quarter rose 40.7% year-on-year to ₹557.8 crore. The company pointed to strong traction in branded generics in India and robust growth in the US and other international markets as key drivers. However, reported earnings were weighed down by one-off items booked during the quarter. Net profit after exceptional items fell 22.7% year-on-year to ₹236.5 crore. The gap between core and reported profit is largely explained by exceptional charges of about ₹135 crore.

What moved profits: operating leverage, then one-offs

The company attributed the improvement in core profit to expanding revenues across geographies and operating leverage, indicating better cost absorption as the topline improved. That translated into a significantly higher pre-exceptional profit base for Q4FY26 at ₹557.8 crore. But exceptional items reduced reported profitability in the same period. Net profit after exceptional items came in at ₹236.5 crore, a decline of 22.7% despite the underlying operating momentum.

The exceptional charges of ~₹135 crore included two large components. First was a ₹60.0 crore liability related to employee benefits following changes under labour codes. Second was a ₹74.7 crore impairment of real estate investments. Together, these items explain why core profitability and reported net profit moved in opposite directions in the quarter.

Domestic business: steady growth led by chronic therapies

In India, Alkem said its domestic business continued to marginally outperform the Indian pharmaceutical market, driven by chronic therapies. The company highlighted anti-diabetic, respiratory, and dermatology segments as areas of strength. Domestic sales in Q4FY26 grew 8.8% year-on-year to ₹2,324.5 crore. The performance reflects continued resilience in branded generics and chronic portfolios, which tend to be less volatile than acute therapy categories.

Management commentary also linked domestic momentum to portfolio strength rather than one-off factors, suggesting the base business remained firm into the end of FY26. The company’s FY27 outlook continues to put India as a key growth driver, with an expectation that domestic business will grow 100–150 basis points above the market.

International business: 25.4% growth and US launches

International sales grew 25.4% in Q4FY26, led by the US business and product launches, according to the company. While the absolute international revenue number for the quarter was not provided in the shared details, Alkem’s commentary underscores the role of overseas markets in driving consolidated growth.

The company also underlined pipeline execution in the US during the quarter. Alkem filed five ANDAs and received four approvals in the US in Q4FY26. This pipeline progress was presented as a support for future growth visibility, especially as the company aims to build a differentiated launch pipeline for international markets.

FY26 financial snapshot: revenue and profitability

For the full year, Alkem reported that consolidated revenue rose to ₹14,712.27 crore in FY26 from ₹12,964.52 crore in FY25. Consolidated net profit increased to ₹2,351.16 crore from ₹2,215.38 crore over the same period. Separately, the company also reported net profit for FY26 at ₹2,301.8 crore, stating it rose 6.3% despite exceptional expenses during the year.

Operating profitability was also supported by higher EBITDA in FY26. FY26 EBITDA stood at ₹3,005.2 crore with a margin of 20.4%, up from 19.4%. For Q4FY26, EBITDA was reported at ₹517.4 crore with a margin of 14.4%, up 32.2% year-on-year.

One table: key reported numbers and one-offs

FY27 guidance: margins, growth mix, and costs

Alkem said it aims to sustain growth and profitability in FY27, with focus on execution, portfolio mix, and a differentiated pipeline. FY27 margin guidance was set at 20–21%, contingent on stabilization of the geopolitical and cost environment. For geography-led growth expectations, the company guided the US pharma business for high single-digit growth (excluding CDMO), while rest-of-world markets are expected to grow in the high teens.

On spending priorities, R&D spend is expected to remain at 4–5% of revenue. Other expenses are expected to rise 7–8% excluding acquisitions. The company also said it has opted for the new tax regime from FY27, with deferred tax recognized at the substantially enacted rate as of 31 March 2026.

Street view: targets and key debate points

Brokerage commentary in the shared details shows a spread of views on execution and margins. Jefferies retained an ‘underperform’ rating and lowered its price target to ₹4,460, citing concerns around execution on new initiatives. Separately, the analyst consensus 12-month price target range cited is ₹4,400–₹5,500, with most brokerages maintaining a Hold/Buy stance. Another reference in the shared details noted Nomura maintained a ‘Buy’ with a ₹5,430 target.

Some analyst notes also pointed to the role of R&D and upfront costs for new growth drivers such as CDMO and medical technology initiatives, which can affect near-term margins. In the company’s own outlook, management positioned FY27 as starting “on a firm foundation,” supported by chronic therapies and international launches.

Why this quarter matters

The Q4FY26 result highlights a clear split between operating performance and reported profitability. A 40.7% rise in core profit suggests underlying momentum in the business, helped by both domestic branded generics and international expansion. But the quarter also shows how exceptional items can materially alter headline earnings. Investors tracking Alkem’s execution will likely focus on whether US filings and approvals translate into consistent launch-led growth while India continues to outperform the market.

Conclusion

Alkem closed Q4FY26 with higher core profit and strong international growth, but exceptional charges of about ₹135 crore pulled down reported net profit. The next key monitorables are FY27 margin delivery within the 20–21% guidance band and progress on the US launch pipeline, following five ANDA filings and four approvals in the quarter.